Zhang Lin, Zhou Chao, Zhang Songou, Chen Xiaozhen, Liu Jian, Xu Fangming, Liang Wenqing
Department of Pharmacy, Shaoxing People's Hospital, Shaoxing Hospital, Zhejiang University School of Medicine, Shaoxing, China.
Department of Orthopedics, Zhoushan Guanghua Hospital, Zhoushan, China.
Front Oncol. 2022 Aug 8;12:939249. doi: 10.3389/fonc.2022.939249. eCollection 2022.
New evidence suggests that the clinical success of chemotherapy is not merely due to tumor cell toxicity but also arises from the restoration of immunosurveillance, which has been immensely neglected in previous preclinical and clinical researches. There is an urgent need for novel insights into molecular mechanisms and regimens that uplift the efficacy of immunotherapy since only a minority of cancer patients are responsive to immune checkpoint inhibitors (ICIs). Recent findings on combination therapy of chemotherapy and ICIs have shown promising results. This strategy increases tumor recognition and elimination by the host immune system while reducing immunosuppression by the tumor microenvironment. Currently, several preclinical studies are investigating molecular mechanisms that give rise to the immunomodulation by chemotherapeutic agents and exploit them in combination therapy with ICIs in order to achieve a synergistic clinical activity. In this review, we summarize studies that exhibit the capacity of conventional chemotherapeutics to elicit anti-tumor immune responses, thereby facilitating anti-tumor activities of the ICIs. In conclusion, combining chemotherapeutics with ICIs appears to be a promising approach for improving cancer treatment outcomes.
新证据表明，化疗的临床成功不仅归因于肿瘤细胞毒性，还源于免疫监视功能的恢复，而这一点在以往的临床前和临床研究中一直被极大地忽视。由于只有少数癌症患者对免疫检查点抑制剂（ICI）有反应，因此迫切需要对提高免疫治疗疗效的分子机制和治疗方案有新的见解。最近关于化疗与ICI联合治疗的研究显示出了有前景的结果。这种策略可增强宿主免疫系统对肿瘤的识别和清除能力，同时减少肿瘤微环境的免疫抑制作用。目前，多项临床前研究正在探究化疗药物引发免疫调节的分子机制，并将其应用于与ICI的联合治疗中，以实现协同的临床活性。在本综述中，我们总结了一些研究，这些研究展示了传统化疗药物引发抗肿瘤免疫反应的能力，从而促进了ICI的抗肿瘤活性。总之，将化疗药物与ICI联合使用似乎是改善癌症治疗效果的一种有前景的方法。
